Home  »  Companies   »  Matinas BioPharma Holdings Inc. (AMEX:MTNB): The F...

Matinas BioPharma Holdings Inc. (AMEX:MTNB): The Fundamentals Have Changed

Matinas BioPharma Holdings Inc. (AMEX:MTNB) previous close was $0.84 while the outstanding shares total 203.87M. The firm has a beta of 2.55. MTNB’s shares traded lower over the last trading session, losing -3.26% on 06/21/21. The shares fell to a low of $0.81 before closing at $0.81. Intraday shares traded counted 1.46 million, which was -8.25% lower than its 30-day average trading volume of 1.35M. The stock’s Relative Strength Index (RSI) is 43.84, with weekly volatility at 7.28% and ATR at 0.05. The MTNB stock’s 52-week price range has touched low of $0.66 and a $2.22 high.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Investors have identified the Biotechnology company Matinas BioPharma Holdings Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $170.04 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Matinas BioPharma Holdings Inc. (MTNB) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 63.14 million total, with 2.22 million as their total liabilities.

MTNB were able to record -4.65 million as free cash flow during the 08/12/2021 quarter of the year, this saw their quarterly net cash flow reduce by 10.95 million. In cash movements, the company had a total of -4.65 million as operating cash flow.

Potential earnings growth for Matinas BioPharma Holdings Inc. (MTNB)

What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 33000.0 trying to sell their products during the last quarter, with the result yielding a gross income of 6.39 million. This allows shareholders to hold on to 203.87M with the recently reported earning now reading -0.02 cents per share. This is a figure that compared to analyst’s prediction for their 08/12/2021 (-0.03 cents a share).

Having a look at the company’s valuation, the company is expected to record -0.11 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on MTNB sounds very interesting.

Is the stock of MTNB attractive?

In related news, Director, STERN ADAM K bought 20,000 shares of the company’s stock in a transaction that recorded on Aug 21. The purchase was performed at an average price of 0.83, for a total value of 16,600. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.40%.

Leave a Comment

Your email address will not be published. Required fields are marked *